Cancer Antigen 19-9 (CA 19-9) with Serum/Plasma
This test measures a protein (antigen) that may be produced in higher amounts by certain cancers, including pancreatic cancer, and sometimes by other types of cancer or non-cancerous conditions.
["CA 19-9 helps monitor cancer progression and response to treatment."]
Key facts at a glance
- LOINC
- 50780-6
- Short code
- CA19-9 PF
- Synonyms
- Cancer Ag19-9 Pcar-aCnc
- Category
- chemistry
- Sample
- serum
- Container
- Sterile, leak-proof container without anticoagulants; red-top vacuum tube acceptable for transport
- Units
- N/A
- Ref low
- 0
- Ref high
- 37
- Critical range
- 0.5 N/A – —
- Fasting
- false
- Population
- adult
- Sex
- all
- Age range
- 18–65 years
- Method
- Immunoassay (Chemiluminescent)
- CPT
- 86316
- SNOMED
- 165539006
- Specimen volume
- 2-5 mL of pericardial fluid
- Stability
- Room temperature: 8 hours; Refrigerated (2-8°C): 7 days; Frozen (-20°C): 3 months
- Hemolysis max
- 500
- Lipemia max
- 1000
- Icterus max
- 500
- TAT
- 24–72 hours
- Order
- routine
What Is CA 19-9 Used For?
CA 19-9 is primarily used to detect or track pancreatic cancer, though it can also be elevated in other cancers like bile duct, stomach, or colorectal cancers. It may also appear in non-cancerous conditions such as chronic pancreatitis or liver disease. This test is often used alongside other diagnostic tools to guide treatment decisions.
How Is the Test Performed?
A blood sample is drawn from a vein, usually in your arm. The blood is then sent to a lab where it is tested for the presence of CA 19-9. The test can be performed on either serum or plasma, depending on the lab’s protocol.
Why Might Your Doctor Order This Test?
Your doctor may order a CA 19-9 test if you have symptoms of pancreatic cancer (such as abdominal pain, unexplained weight loss, or jaundice), if you have a history of pancreatic cancer or other related cancers, or if you are undergoing treatment for these conditions. It can also be used to monitor cancer spread or treatment effectiveness.
What Do Results Mean?
Elevated levels of CA 19-9 can indicate cancer, but they can also be raised in non-cancerous conditions. A single elevated result does not definitively diagnose cancer. Your doctor will consider your symptoms, medical history, and other test results to interpret the results accurately.
Reference range
No established reference range for pericardial fluid; serum reference range <37 U/mL is commonly applied as interpretive baselineN/A
No special patient preparation required for pericardial fluid sampling; pericardiocentesis performed by qualified clinician
Clinical interpretation
How abnormal results are interpreted and what conditions they suggest.
CA 19-9 is a tumor marker that can be useful in diagnosing pancreatic cancer and assessing its progression. However, it is not specific to cancer alone, so it should be used alongside other diagnostic tests and clinical findings. High levels may suggest cancer, but further testing is required to confirm a diagnosis. Regular monitoring of CA 19-9 levels can help track cancer activity during treatment.
Short name
CA 19-9 Test
Frequently asked questions
What Are the Possible Causes of Elevated CA 19-9 Levels?
How Often Should I Get This Test?
Can CA 19-9 Levels Decrease After Treatment?
Sources
- 1
- 2Lab Tests OnlineSource
- 3
Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 17, 2026. · Read our editorial policy